Tango Therapeutics Launches $500M Public Offering

Tango Therapeutics, a clinical-stage biotechnology company, announced the launch of an underwritten public offering to sell $500 million of its common stock. The company also intends to grant the underwriters a 30-day option to purchase up to an additional $75 million in shares. J.P. Morgan, Leerink Partners, Cantor, and Stifel are acting as joint bookrunning managers for the offering. The offering is subject to market conditions, and there is no assurance regarding its completion, actual size, or terms.